Contract development and manufacturing organisations Vetter and Rentschler Biopharma have announced a strategic collaboration designed to enhance their services and offering across the biopharmaceutical value chain.
The companies said the goal of the collaboration is to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.
Vetter is a member of AusBiotech.
“We are pleased to collaborate with such a highly respected and successful company. Like us, Vetter is a family-run and well-established service provider. We have known each other for many years and share a commitment to high-quality standards and sustainable value creation. Our strategic collaboration is aimed at reducing complexity for our clients, with the joint overarching goal of bringing promising new therapies to patients with serious and rare diseases faster than before,” stated Professor Dr Nikolaus F. Rentschler, chairman of the board of Rentschler Biopharma.
Senator h.c. Udo J. Vetter, chairman of the advisory board of Vetter, added, “It is important for businesses to sometimes think outside the box. Pursuing future-oriented and innovative ideas is part of both of our companies’ DNA. The alignment of Rentschler Biopharma’s experience in drug substance manufacturing and our own core competency in drug product pharmaceutical manufacturing is yet another opportunity to pursue.”
The companies said their collaboration will leverage Rentschler Biopharma’s experience in drug substance manufacturing, including bioprocess development and API production, with Vetter’s expertise in aseptic fill and finish and secondary packaging.
"The companies have already identified opportunities, where early and active exchange of know-how and best-practice will benefit both clients and their drug products. Over the next months, these opportunities will be further validated in pilot client projects with joint teams from both companies," they said.
“We are excited to team up with Vetter to complement our customized development and manufacturing solutions for even the most complex biopharmaceuticals,” said Dr Frank Mathias, CEO of Rentschler Biopharma.
“Vetter is adding a wealth of expertise for clinical and commercial drug product supply, well suited to the maturing product pipeline of our clients. Their services are a great fit to our own offering. Our collaboration holds great promise for further simplifying client solutions, while expanding the boundaries of what is possible in biopharmaceutical production.”
Peter Soelkner, managing director of Vetter added, “There are important synergies between our business portfolios that will provide valuable market foresight that can positively impact our clients’ business and patients’ treatment. Combining our experience enables us to deliver new efficiencies and pathways that streamline the development and the supply chain in ways that address the challenges of complexity companies across the industry are facing.”